Drug Trial Radar · NCT06777316
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Jan 22, 2025
Primary completion
Mar 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Cogent Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.
Conditions
- Intrahepatic Cholangiocarcinoma (Icc)
- Cholangiocarcinoma
- Other Solid Tumors, Adult
- FGFR2 Gene Fusion/Rearrangement
- FGFR2 Gene Amplification
- FGFR2 Gene Short Variants
- FGFR3 Gene Fusion/Rearrangement
- FGFR3 Gene Amplification
- FGFR3 Gene Short Variants
- FGFR2 Genetic Alterations
- FGFR3 Genetic Alterations
- Advanced Solid Tumors
Interventions
CGT4859Drug
CGT4859 is a selective FGFR2/3 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - AEsTime frame: Approximately 12 months
- Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - Laboratory resultsTime frame: Approximately 12 months
- Phase 1: Determine the maximum tolerated dose (MTD) and RP2D of CGT4859 - ECG resultsTime frame: Approximately 12 months
- Phase 2: Evaluate antitumor activity of CGT4859 - Objective Response Rate (ORR)Time frame: Approximately 8 months
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Stanford Cancer Institute
Palo Alto, California
Mayo Clinic Jacksonville
Jacksonville, Florida
Moffitt Cancer Center
Tampa, Florida
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Mayo Clinic Rochester
Rochester, Minnesota
The Christ Hospital
Cincinnati, Ohio
Taussig Cancer Center - Cleveland Clinic
Cleveland, Ohio
Fox Chase cancer Center
Philadelphia, Pennsylvania
Tennessee Oncology
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute - University of Utah
Salt Lake City, Utah
Princess Margaret Cancer Centre - UHN
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.